Waverley Pharma Inc (V:WAVE) — Market Cap & Net Worth
Market Cap & Net Worth: Waverley Pharma Inc (WAVE)
Waverley Pharma Inc (V:WAVE) has a market capitalization of $585.94K (CA$810.00K) as of August 27, 2026. Listed on the V stock exchange, this Canada-based company holds position #30933 globally and #1636 in its home market, demonstrating a -40.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Waverley Pharma Inc's stock price CA$0.02 by its total outstanding shares 54000000 (54.00 Million). Check WAVE live share price for real-time trading data and today's change.
Waverley Pharma Inc Market Cap History: 2017 to 2026
Waverley Pharma Inc's market capitalization history from 2017 to 2026. Data shows change from $17.58 Million to $585.94K (-26.14% CAGR).
Waverley Pharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Waverley Pharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check WAVE book value to evaluate the company's book value and shareholders' equity.
Latest Price to Sales (P/S) Ratio
0.58x
Waverley Pharma Inc's market cap is 0.58 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $10.94 Million | $223.40K | -$1.42 Million | 48.96x | N/A |
| 2019 | $3.91 Million | $1.16 Million | -$1.21 Million | 3.38x | N/A |
| 2020 | $4.88 Million | $1.38 Million | -$705.76K | 3.55x | N/A |
| 2021 | $3.13 Million | $1.75 Million | -$796.51K | 1.78x | N/A |
| 2022 | $1.17 Million | $1.25 Million | -$664.08K | 0.94x | N/A |
| 2023 | $976.57K | $412.09K | -$2.22 Million | 2.37x | N/A |
| 2024 | $390.63K | $475.37K | -$947.08K | 0.82x | N/A |
| 2025 | $781.26K | $1.35 Million | -$499.21K | 0.58x | N/A |
Competitor Companies of WAVE by Market Capitalization
Companies near Waverley Pharma Inc in the global market cap rankings as of August 27, 2026. Also see Waverley Pharma Inc (WAVE) cash flow conversion for how efficiently the company converts equity into cash flow.
Key companies related to Waverley Pharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #191 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #329 globally with a market cap of $82.41 Billion USD.
- CSL Ltd (AU:CSL): Ranked #466 globally with a market cap of $59.19 Billion USD ( AU$83.66 Billion AUD).
- Samsung Biologics Co Ltd (KO:207940): Ranked #552 globally with a market cap of $50.16 Billion USD ( ₩74.02 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #191 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.29 |
| #329 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $82.41 Billion | $814.79 |
| #466 | CSL Ltd | AU:CSL | $59.19 Billion | AU$172.44 |
| #552 | Samsung Biologics Co Ltd | KO:207940 | $50.16 Billion | ₩1599000.00 |
Waverley Pharma Inc Historical Marketcap From 2017 to 2026
Between 2017 and today, Waverley Pharma Inc's market cap moved from $17.58 Million to $ 585.94K, with a yearly change of -26.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$585.94K | -25.00% |
| 2025 | CA$781.26K | +100.00% |
| 2024 | CA$390.63K | -60.00% |
| 2023 | CA$976.57K | -16.67% |
| 2022 | CA$1.17 Million | -62.50% |
| 2021 | CA$3.13 Million | -36.00% |
| 2020 | CA$4.88 Million | +25.00% |
| 2019 | CA$3.91 Million | -64.29% |
| 2018 | CA$10.94 Million | -37.78% |
| 2017 | CA$17.58 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 27th, 2026 the market cap of Waverley Pharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $585.94K USD |
| MoneyControl | $585.94K USD |
| MarketWatch | $585.94K USD |
| marketcap.company | $585.94K USD |
| Reuters | $585.94K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Waverley Pharma Inc
Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops PARP-1 Inhibitors for cancer treatment. It also operates a retail pharmacy in the United States. In addition, it is involved in the sale of prescription medications, over-the-counter products, and associated pharmacy services. Waverley Pharm… Read more